Chinese researchers have achieved a significant breakthrough in biopharmaceutical science by developing a method to produce human serum albumin (HSA) from genetically modified rice. This is reported by China Daily, a partner of TV BRICS.

In 2024, China consumed over 1,000 tonnes of HSA, with more than two-thirds sourced through imports.

This innovative rice-based method uses advanced genetic engineering to insert human genes into rice plants, allowing them to express and synthesise HSA. According to researchers, a single 25-kilogram sack of modified rice can yield the equivalent amount of HSA found in five litres of human plasma.

Currently, the production facility has the capacity to generate 10 tonnes of HSA annually. With a second plant expected to commence operations in 2026, the combined output is projected to rise to 130 tonnes per year, potentially replacing around 25 per cent of the HSA currently imported into China.

Results have confirmed that the protein’s efficacy is equivalent to conventional plasma-derived albumin. It also offers a scalable and pathogen-free solution to global albumin shortages.

African Times published this article in partnership with International Media Network TV BRICS